Y Intercept Hong Kong Ltd Sells 18,025 Shares of Elevance Health, Inc. $ELV

Y Intercept Hong Kong Ltd lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 76.5% in the third quarter, Holdings Channel.com reports. The fund owned 5,522 shares of the company’s stock after selling 18,025 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Elevance Health were worth $1,784,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Vermillion & White Wealth Management Group LLC increased its position in shares of Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares during the period. BOK Financial Private Wealth Inc. purchased a new position in shares of Elevance Health in the 2nd quarter valued at approximately $32,000. Motco grew its stake in Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 77 shares during the period. True Wealth Design LLC raised its holdings in Elevance Health by 431.8% in the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock worth $38,000 after purchasing an additional 95 shares in the last quarter. Finally, Glass Jacobson Investment Advisors llc boosted its holdings in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after buying an additional 80 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat expectations — ELV reported $3.33 EPS, topping consensus and showing growth in premiums and Carelon revenue, which helped lift sentiment. Elevance Health (ELV) Beats Q4 Earnings Estimates
• Positive Sentiment: Market reaction to the results pushed the stock higher in some sessions — coverage noted a sharp intraday jump tied to the earnings beat. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Dividend increase: quarterly dividend raised to $1.72 (annual yield ~2.0%), a small raise that supports income-oriented investors and signals confidence in cash flow.
• Positive Sentiment: Brokerage sentiment is constructive — recent survey shows an average “Moderate Buy” rating, which can underpin buying interest after volatility. Elevance Health, Inc. (NYSE:ELV) Given Average Recommendation of “Moderate Buy” by Brokerages
• Neutral Sentiment: Earnings call highlights show strong operational points (premiums, Carelon growth) but also mixed metrics (membership slip, higher expenses) — results are not a clear-cut upgrade to 2026 profitability. Elevance Health Inc (ELV) Q4 2025 Earnings Call Highlights: Strong Financial Performance Amid …
• Negative Sentiment: Company flagged 2026 profit guidance below Street estimates and warned of a revenue decline next year — this guidance is the main headwind to the stock’s rally. Elevance forecasts 2026 profit below estimates, flags revenue decline
• Negative Sentiment: Regulatory pressure: CMS proposed only a 0.09% raise to Medicare Advantage rates for 2027, which exacerbates investor concerns about Medicare-related reimbursement pressure and has contributed to recent selloffs. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Analyst and market write-ups point to persistent margin pressure and membership shifts that may keep earnings upside limited until guidance/Medicare clarity improves. Elevance Health Q4 Earnings Review: No Sign Of An End To The Pain

Analyst Upgrades and Downgrades

ELV has been the topic of several research reports. Guggenheim dropped their price objective on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research note on Thursday. Barclays set a $393.00 target price on Elevance Health in a research note on Friday. Truist Financial set a $400.00 price objective on shares of Elevance Health in a research report on Tuesday, October 14th. JPMorgan Chase & Co. upped their target price on shares of Elevance Health from $384.00 to $394.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Finally, Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Twelve equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $397.42.

Elevance Health Stock Performance

NYSE:ELV opened at $346.33 on Friday. The firm has a market capitalization of $76.97 billion, a PE ratio of 13.79, a PEG ratio of 1.86 and a beta of 0.51. The stock’s fifty day moving average is $351.21 and its 200 day moving average is $328.99. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter in the previous year, the business posted $3.84 earnings per share. The business’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.96%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.